{"schema":"sb.node.v1","id":"sb:e/71b5797c246f44f17065c375","kind":"entity","label":{"text":"foundayo","locale":"en"},"identity":{"anchor":"label:en:foundayo","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T17:31:13.825968+00:00","snapshot":"deploy 0213c6200d34bd9327cf8fb2d5bb00702183a24b"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":27,"separatePublishers":16,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-06","to":"2026-10-03","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.259: about 74% of mentions carry no typed assertion"]}},"dimensions":{"domains":["fda_decisions","auto"],"activeDays":17,"assertions":{"utterance":3,"launch-release":2,"regulatory-approval":1,"price-threshold":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/52462be02c3930e732298b77","kind":"observation","label":"Fierce Pharma · 2026-10-01 · Lilly gives deeper glimpse at Foundayo's heart-helping odds in diabetes, obesity phase 3","url":"https://www.fiercepharma.com/pharma/lilly-gives-deeper-glimpse-foundayos-heart-helping-odds-diabetes-obesity-phase-3"},{"id":"sb:o/0fc334316370238ac476df54","kind":"observation","label":"Medical Daily · 2026-10-03 · Rhode Island Medicaid Ends Coverage of Wegovy, Zepbound, and Other GLP-1 Drugs Prescribed Only for Weight Loss","url":"https://www.medicaldaily.com/rhode-island-medicaid-glp1-weight-loss-coverage-ends-479465"},{"id":"sb:o/88f2eba6f0215e98f5b7a64b","kind":"observation","label":"European Medical Journal · 2026-10-03 · Forghorn slashes workforce by 40% after deal with Eli Lilly ends","url":"https://www.emjreviews.com/emj-gold/news/forghorn-slashes-workforce-by-40-after-deal-with-eli-lilly-ends/"},{"id":"sb:o/544abccfc10dbc420f2c8392","kind":"observation","label":"Chemical & Engineering News · 2026-10-01 · Weight-loss-drug makers unveil new data and deals","url":"https://cen.acs.org/pharmaceuticals/weight-loss-drug-makers-unveil-new-data-deals/104/web/2026/09?sc=230901_cenrssfeed_eng_latestnewsrss_cen"},{"id":"sb:o/3455378ae89397041503ee36","kind":"observation","label":"Fierce Pharma · 2026-09-30 · Novo, Lilly pit their GLP-1s against one another in diabetes and obesity as EASD kicks off in Milan","url":"https://www.fiercepharma.com/pharma/novo-lilly-pit-their-glp-1s-against-one-another-diabetes-and-obesity-easd-kicks-milan"},{"id":"sb:o/29911e419b8acb94a6056ef5","kind":"observation","label":"Clinical Trials Arena · 2026-09-30 · Lilly reports comparative data from ACHIEVE-3 and PIONEER PLUS studies","url":"https://www.clinicaltrialsarena.com/news/lilly-achieve-3-pioneer-plus-data/"},{"id":"sb:o/3568674abae3447c80809e91","kind":"observation","label":"Fierce Pharma · 2026-09-29 · Eli Lilly's new initiative will take GLP-1s to lower-income nations","url":"https://www.fiercepharma.com/pharma/lillys-new-initiative-will-take-glp-1s-lower-income-nations"},{"id":"sb:o/90f8adab7cc9396288246572","kind":"observation","label":"PR Daily · 2026-09-28 · The Scoop: Eli Lilly defends presence at Vogue World","url":"https://www.prdaily.com/the-scoop-eli-lilly-defends-presence-at-vogue-world/"},{"id":"sb:o/f53fc1a6ee4e50ac99ded5d2","kind":"observation","label":"24/7 Wall St. · 2026-09-28 · Eli Lilly Wavered Over the Last Month: One of Wall Street’s Biggest Banks Says 35% Gains Still to Come","url":"https://247wallst.com/investing/2026/09/28/eli-lilly-wavered-over-the-last-month-one-of-wall-streets-biggest-banks-says-35-gains-still-to-come/"},{"id":"sb:o/eb7623f2c5fa7d63366c036d","kind":"observation","label":"The Guardian · 2026-09-27 · ‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event","url":"https://www.theguardian.com/fashion/2026/sep/27/weight-loss-pill-company-eli-lilly-vogue-world-ties-concerns-health-campaigners"}],"cursor":"c1.eyJpZCI6InNiOmUvNzFiNTc5N2MyNDZmNDRmMTcwNjVjMzc1IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA4VDE3OjMxOjEzLjgyNTk2OCswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":7,"byKind":{"co-mentioned":7},"items":[{"kind":"relation","label":"co-mentioned with eli lilly (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d23372160e7450775f297e61"},{"kind":"relation","label":"co-mentioned with glp-1 (24 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/81ded3bd116029345b2c32cb"},{"kind":"relation","label":"co-mentioned with zepbound (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e19b7b85b945ca24862c1642"},{"kind":"relation","label":"co-mentioned with fda (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a29bd6bb5743cd2e38f4296e"},{"kind":"relation","label":"co-mentioned with mounjaro (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/58e9362317f1602f707cbfa4"},{"kind":"relation","label":"co-mentioned with novo nordisk (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/6dda7ff4fafa6a4802433688"},{"kind":"relation","label":"co-mentioned with glp-1s (8 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ab1ea1446fbed6a1387ee670"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/71b5797c246f44f17065c375","mcp":"traverse {\"id\":\"sb:e/71b5797c246f44f17065c375\"}","page":"/entity/foundayo/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/71b5797c246f44f17065c375\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/71b5797c246f44f17065c375\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/71b5797c246f44f17065c375\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/71b5797c246f44f17065c375\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}